Mylan wraps up $5.3B Abbott portfolio buyout; Novo raises IPO price on NNIT subsidiary;

@FiercePharma: Oculus leaps into animal health with 6 new skin and eye products. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bayer counts on consumer health, pharma growth to power 2015. Story | Follow @CarlyHFierce

> Mylan ($MYL) wrapped up its $5.3 billion buyout of a portfolio of Abbott Laboratories' ($ABT) specialty and branded generics, focused on developed markets outside the U.S.; the deal gives Mylan a new, tax-friendly location in the Netherlands and more heft in international markets. Release

> Novo Nordisk ($NVO) hiked the price range for its planned IPO for the technology services subsidiary NNIT, to 120 to 130 Danish crowns ($18 to $19) from 100 to 120 crowns. Report

> Actavis ($ACT) reportedly has started marketing bonds in a 9-part offering worth as much as $22 billion; the debt sale will finance its buyout of Botox-maker Allergan ($AGN). Report

> The FDA rejected Pacira Pharmaceuticals' application to expand the use of Exparel, a treatment for surgery-related pain, to other nerve-numbing uses. Report

> An Actavis intrauterine device that releases the hormone levonorgestrel, Liletta, won FDA approval to prevent pregnancy for up to three years. Report

> The FDA is requiring additional warnings on multidose diabetes pens, prohibiting patients from sharing the devices, because of the risk of infection. Report

Medical Device News

@FierceMedDev: Startup Akili partners with nonprofit Autism Speaks to test video game. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI: More lawsuits planned as infected endoscope safety scare grows. More | Follow @VarunSaxena2

> J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation. Story

> FDA approves Actavis intrauterine device to prevent pregnancy. Article

> Startup Akili partners with nonprofit Autism Speaks to test video game. More

Biotech News

@FierceBiotech: From FierceDrugDelivery: UPDATED: @US_FDA agrees to review $ENDP's inside-the-cheek pain drug. More | Follow @FierceBiotech

@JohnCFierce: Interested in ADCs and VC cash? Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm. Article | Follow @JohnCFierce

@DamianFierce: The fake Immunovaccine release reads like a parody of bio stock pumping. Image | Follow @DamianFierce

> As PhII data looms, Chugai inks a $205M stem cell deal with Athersys. Article

> Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease. Report

> China biotech makes FDA 'breakthrough' for HIV drug. Item

Biotech IT News

> RainDance files for $60M IPO. Item

> Novo Nordisk set to rake in up to $335M from IT unit IPO. Report

> Eccrine bags seed funding for Air Force-developed sweat sensor. News

> Analyst casts doubt on Big Data potential of Covance-LabCorp merger. Story

> H3 hooks up with Foundation Medicine for data-driven oncology R&D. Article

CRO News

> Charles River embraces discovery in management shake-up. News

> Catalent beefs up its European network for clinical supplies. Story

> Enteris gets into contract manufacturing with new plant. Item

> INC Research soars in its first post-IPO quarter. Report

> Icon rides a revenue leap into another growth year. Article

Animal Health News

> Bayer to close animal health plant in St. Joseph, MO; sell-off some product lines. More

> Aratana regains dog lymphoma drug from Lilly for 'great price,' say analysts. Story

> Purina faces lawsuit over dogs allegedly sickened by Beneful. Item

> Oculus leaps into animal health with 6 new skin and eye products. Article

> Parnell records strong sales growth, stays focused on arthritis approval. Report

And Finally... India has tightened up its healthcare budget for 2015-2016, a move that disappointed advocates of improved access to care. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.